Point72 Asia Singapore Pte. Ltd. Buys Shares of 2,128 IQVIA Holdings Inc. (NYSE:IQV)

Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor purchased 2,128 shares of the medical research company’s stock, valued at approximately $504,000.

A number of other institutional investors and hedge funds have also modified their holdings of IQV. First Foundation Advisors raised its position in shares of IQVIA by 3.8% during the 2nd quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock valued at $245,000 after acquiring an additional 43 shares during the last quarter. Invera Wealth Advisors LLC lifted its stake in IQVIA by 0.3% in the second quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock valued at $3,183,000 after buying an additional 46 shares during the period. Private Trust Co. NA boosted its holdings in IQVIA by 10.7% during the third quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock worth $115,000 after buying an additional 47 shares during the last quarter. Oregon Public Employees Retirement Fund grew its position in shares of IQVIA by 0.3% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock worth $3,313,000 after buying an additional 48 shares during the period. Finally, Continuum Advisory LLC increased its stake in shares of IQVIA by 3.3% in the 2nd quarter. Continuum Advisory LLC now owns 1,538 shares of the medical research company’s stock valued at $325,000 after acquiring an additional 49 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Up 0.5 %

IQVIA stock opened at $201.79 on Tuesday. The company has a market capitalization of $36.62 billion, a PE ratio of 26.48, a PEG ratio of 2.07 and a beta of 1.49. The firm’s fifty day moving average is $217.89 and its 200 day moving average is $225.88. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73.

Analyst Ratings Changes

Several research analysts recently weighed in on IQV shares. Robert W. Baird reduced their price objective on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating on the stock in a research note on Friday, November 1st. Deutsche Bank Aktiengesellschaft decreased their price target on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday, November 1st. Leerink Partners reaffirmed an “outperform” rating and set a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Evercore ISI reduced their target price on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Finally, The Goldman Sachs Group lowered their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. Five research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $256.50.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.